Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 168

1.

Molecular distinction of chondrosarcoma from chondroblastic osteosarcoma through IDH1/2 mutations.

Kerr DA, Lopez HU, Deshpande V, Hornicek FJ, Duan Z, Zhang Y, Rosenberg AE, Borger DR, Nielsen GP.

Am J Surg Pathol. 2013 Jun;37(6):787-95. doi: 10.1097/PAS.0b013e31827ab703.

PMID:
23598960
2.

IDH1 and IDH2 mutations are frequent events in central chondrosarcoma and central and periosteal chondromas but not in other mesenchymal tumours.

Amary MF, Bacsi K, Maggiani F, Damato S, Halai D, Berisha F, Pollock R, O'Donnell P, Grigoriadis A, Diss T, Eskandarpour M, Presneau N, Hogendoorn PC, Futreal A, Tirabosco R, Flanagan AM.

J Pathol. 2011 Jul;224(3):334-43. doi: 10.1002/path.2913. Epub 2011 May 19.

PMID:
21598255
3.

Diagnostic utility of IDH1/2 mutations to distinguish dedifferentiated chondrosarcoma from undifferentiated pleomorphic sarcoma of bone.

Chen S, Fritchie K, Wei S, Ali N, Curless K, Shen T, Brini AT, Latif F, Sumathi V, Siegal GP, Cheng L.

Hum Pathol. 2017 Jul;65:239-246. doi: 10.1016/j.humpath.2017.05.015. Epub 2017 May 25.

PMID:
28552826
4.

Isocitrate dehydrogenase 2 mutation is a frequent event in osteosarcoma detected by a multi-specific monoclonal antibody MsMab-1.

Liu X, Kato Y, Kaneko MK, Sugawara M, Ogasawara S, Tsujimoto Y, Naganuma Y, Yamakawa M, Tsuchiya T, Takagi M.

Cancer Med. 2013 Dec;2(6):803-14. doi: 10.1002/cam4.149. Epub 2013 Oct 17.

5.

Frequent IDH1/2 mutations in intracranial chondrosarcoma: a possible diagnostic clue for its differentiation from chordoma.

Arai M, Nobusawa S, Ikota H, Takemura S, Nakazato Y.

Brain Tumor Pathol. 2012 Oct;29(4):201-6. doi: 10.1007/s10014-012-0085-1. Epub 2012 Feb 10.

PMID:
22323113
6.

Mutant IDH1 Dysregulates the Differentiation of Mesenchymal Stem Cells in Association with Gene-Specific Histone Modifications to Cartilage- and Bone-Related Genes.

Jin Y, Elalaf H, Watanabe M, Tamaki S, Hineno S, Matsunaga K, Woltjen K, Kobayashi Y, Nagata S, Ikeya M, Kato T Jr, Okamoto T, Matsuda S, Toguchida J.

PLoS One. 2015 Jul 10;10(7):e0131998. doi: 10.1371/journal.pone.0131998. eCollection 2015.

7.

Isocitrate dehydrogenase 1 mutations (IDH1) and p16/CDKN2A copy number change in conventional chondrosarcomas.

Amary MF, Ye H, Forbes G, Damato S, Maggiani F, Pollock R, Tirabosco R, Flanagan AM.

Virchows Arch. 2015 Feb;466(2):217-22. doi: 10.1007/s00428-014-1685-4. Epub 2014 Nov 29.

8.

Analysis of IDH1 and IDH2 mutations in Japanese glioma patients.

Sonoda Y, Kumabe T, Nakamura T, Saito R, Kanamori M, Yamashita Y, Suzuki H, Tominaga T.

Cancer Sci. 2009 Oct;100(10):1996-8. doi: 10.1111/j.1349-7006.2009.01270.x.

9.

IDH1 and IDH2 gene mutations identify novel molecular subsets within de novo cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B study.

Marcucci G, Maharry K, Wu YZ, Radmacher MD, Mrózek K, Margeson D, Holland KB, Whitman SP, Becker H, Schwind S, Metzeler KH, Powell BL, Carter TH, Kolitz JE, Wetzler M, Carroll AJ, Baer MR, Caligiuri MA, Larson RA, Bloomfield CD.

J Clin Oncol. 2010 May 10;28(14):2348-55. doi: 10.1200/JCO.2009.27.3730. Epub 2010 Apr 5.

10.

IDH1 and IDH2 mutations are prognostic but not predictive for outcome in anaplastic oligodendroglial tumors: a report of the European Organization for Research and Treatment of Cancer Brain Tumor Group.

van den Bent MJ, Dubbink HJ, Marie Y, Brandes AA, Taphoorn MJ, Wesseling P, Frenay M, Tijssen CC, Lacombe D, Idbaih A, van Marion R, Kros JM, Dinjens WN, Gorlia T, Sanson M.

Clin Cancer Res. 2010 Mar 1;16(5):1597-604. doi: 10.1158/1078-0432.CCR-09-2902. Epub 2010 Feb 16.

11.

Inhibition of mutant IDH1 decreases D-2-HG levels without affecting tumorigenic properties of chondrosarcoma cell lines.

Suijker J, Oosting J, Koornneef A, Struys EA, Salomons GS, Schaap FG, Waaijer CJ, Wijers-Koster PM, Briaire-de Bruijn IH, Haazen L, Riester SM, Dudakovic A, Danen E, Cleton-Jansen AM, van Wijnen AJ, Bovée JV.

Oncotarget. 2015 May 20;6(14):12505-19.

12.

Galectin-1 is a powerful marker to distinguish chondroblastic osteosarcoma and conventional chondrosarcoma.

Gomez-Brouchet A, Mourcin F, Gourraud PA, Bouvier C, De Pinieux G, Le Guelec S, Brousset P, Delisle MB, Schiff C.

Hum Pathol. 2010 Sep;41(9):1220-30. doi: 10.1016/j.humpath.2009.10.028. Epub 2010 Apr 18.

PMID:
20399482
13.

Type and frequency of IDH1 and IDH2 mutations are related to astrocytic and oligodendroglial differentiation and age: a study of 1,010 diffuse gliomas.

Hartmann C, Meyer J, Balss J, Capper D, Mueller W, Christians A, Felsberg J, Wolter M, Mawrin C, Wick W, Weller M, Herold-Mende C, Unterberg A, Jeuken JW, Wesseling P, Reifenberger G, von Deimling A.

Acta Neuropathol. 2009 Oct;118(4):469-74. doi: 10.1007/s00401-009-0561-9. Epub 2009 Jun 25.

PMID:
19554337
14.

IDH1 and IDH2 mutation analysis in Chinese patients with acute myeloid leukemia and myelodysplastic syndrome.

Lin J, Yao DM, Qian J, Chen Q, Qian W, Li Y, Yang J, Wang CZ, Chai HY, Qian Z, Xiao GF, Xu WR.

Ann Hematol. 2012 Apr;91(4):519-25. doi: 10.1007/s00277-011-1352-7. Epub 2011 Oct 14.

PMID:
21997850
15.

Genetic characterization of mesenchymal, clear cell, and dedifferentiated chondrosarcoma.

Meijer D, de Jong D, Pansuriya TC, van den Akker BE, Picci P, Szuhai K, Bovée JV.

Genes Chromosomes Cancer. 2012 Oct;51(10):899-909. doi: 10.1002/gcc.21974. Epub 2012 Jun 4.

PMID:
22674453
16.

Analysis of NADP+-dependent isocitrate dehydrogenase-1/2 gene mutations in pediatric brain tumors: report of a secondary anaplastic astrocytoma carrying the IDH1 mutation.

Mascelli S, Raso A, Biassoni R, Severino M, Sak K, Joost K, Milanaccio C, Barra S, Grillo-Ruggieri F, Vanni I, Consales A, Cama A, Capra V, Nozza P, Garrè ML.

J Neurooncol. 2012 Sep;109(3):477-84. doi: 10.1007/s11060-012-0925-1. Epub 2012 Jul 22.

PMID:
22821382
17.

Isocitrate dehydrogenase mutation is frequently observed in giant cell tumor of bone.

Kato Kaneko M, Liu X, Oki H, Ogasawara S, Nakamura T, Saidoh N, Tsujimoto Y, Matsuyama Y, Uruno A, Sugawara M, Tsuchiya T, Yamakawa M, Yamamoto M, Takagi M, Kato Y.

Cancer Sci. 2014 Jun;105(6):744-8. doi: 10.1111/cas.12413.

18.

Mutation of p53 with loss of heterozygosity in the osteosarcomatous component of a dedifferentiated chondrosarcoma.

Grote HJ, Schneider-Stock R, Neumann W, Roessner A.

Virchows Arch. 2000 May;436(5):494-7.

PMID:
10881744
19.

Diagnostic use of IDH1/2 mutation analysis in routine clinical testing of formalin-fixed, paraffin-embedded glioma tissues.

Horbinski C, Kofler J, Kelly LM, Murdoch GH, Nikiforova MN.

J Neuropathol Exp Neurol. 2009 Dec;68(12):1319-25. doi: 10.1097/NEN.0b013e3181c391be.

PMID:
19915484
20.

Glandular differentiation in dedifferentiated chondrosarcoma: molecular evidence of a rare phenomenon.

Jour G, Liu Y, Ricciotti R, Pritchard C, Hoch BL.

Hum Pathol. 2015 Sep;46(9):1398-404. doi: 10.1016/j.humpath.2015.05.018. Epub 2015 Jun 5.

PMID:
26198745

Supplemental Content

Support Center